1.Enhancing medical compliance of patients with convulsive epilepsy in rural community: a randomized intervention trial.
Li J1, Si Y, Hu J, Liu L, Deng Y, He J, Zhang NM, Zhou D. Epilepsia. 2013 Nov;54(11):1988-96. doi: 10.1111/epi.12382. Epub 2013 Sep 30.
PURPOSE: This randomized intervention trial was to determine whether the implementation of a practical intervention was effective in enhancing medical compliance and improving seizure control among patients with convulsive epilepsy in rural communities in western China.
2.N-(2,6-dimethoxypyridine-3-yl)-9-methylcarbazole-3-sulfonamide as a novel tubulin ligand against human cancer.
Wang YM1, Hu LX, Liu ZM, You XF, Zhang SH, Qu JR, Li ZR, Li Y, Kong WJ, He HW, Shao RG, Zhang LR, Peng ZG, Boykin DW, Jiang JD. Clin Cancer Res. 2008 Oct 1;14(19):6218-27. doi: 10.1158/1078-0432.CCR-08-0550.
PURPOSE: We have synthesized a new tubulin ligand N-(2,6-dimethoxypyridine-3-yl)-9-methylcarbazole-3-sulfonamide (IG-105). This work investigates its anticancer effect and mechanism.